Flucelvax Tetra

Country: European Union

Language: Slovenian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

A/Darwin/6/2021(H3N2)-like strain (A/Darwin/11/2021, wild type) / A/Wisconsin/67/2022 (H1N1)pdm09-like strain (A/Georgia/12/2022 CVR-167) / B/Austria/1359417/2021-like strain (B/Singapore/WUH4618/2021) / B/Phuket/3073/2013-like virus (B/Singapore/INFTT-16-0610/2016, wild type)

Available from:

Seqirus Netherlands B.V.

ATC code:

J07BB02

INN (International Name):

influenza vaccine (surface antigen, inactivated, prepared in cell cultures)

Therapeutic group:

gripi, inaktivirano, split virus ali površinski antigen

Therapeutic area:

Gripa, človek

Therapeutic indications:

Prophylaxis of influenza in adults and children from 2 years of age. Flucelvax Tetra je treba uporabljati v skladu z uradnimi priporočili.

Product summary:

Revision: 14

Authorization status:

Pooblaščeni

Authorization date:

2018-12-12

Patient Information leaflet

                                21
6.
POSEBNO OPOZORILO O SHRANJEVANJU ZDRAVILA ZUNAJ DOSEGA IN
POGLEDA OTROK
Zdravilo shranjujte nedosegljivo otrokom!
7.
DRUGA POSEBNA OPOZORILA, ČE SO POTREBNA
8.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP:
9.
POSEBNA NAVODILA ZA SHRANJEVANJE
Shranjujte v hladilniku.
Ne zamrzujte.
Napolnjeno injekcijsko brizgo shranjujte v škatli za zagotovitev
zaščite pred svetlobo.
10.
POSEBNI VARNOSTNI UKREPI ZA ODSTRANJEVANJE NEUPORABLJENIH
ZDRAVIL ALI IZ NJIH NASTALIH ODPADNIH SNOVI, KADAR SO POTREBNI
11.
IME IN NASLOV IMETNIKA DOVOLJENJA ZA PROMET Z ZDRAVILOM
Seqirus Netherlands B.V.
Paasheuvelweg 28
1105BJ Amsterdam
Nizozemska
12.
ŠTEVILKA(E) DOVOLJENJA (DOVOLJENJ) ZA PROMET
EU/1/18/1326/001 10 napolnjenih injekcijskih brizg brez igle
EU/1/18/1326/002 1 napolnjena injekcijska brizga z iglo
EU/1/18/1326/003 10 napolnjenih injekcijskih brizg z iglo
EU/1/18/1326/004 1 napolnjena injekcijska brizga brez igle
13.
ŠTEVILKA SERIJE
Lot:
14.
NAČIN IZDAJANJA ZDRAVILA
15.
NAVODILA ZA UPORABO
22
16.
PODATKI V BRAILLOVI PISAVI
Sprejeta je utemeljitev, da Braillova pisava ni potrebna.
17.
EDINSTVENA OZNAKA – DVODIMENZIONALNA ČRTNA KODA_ _
Vsebuje dvodimenzionalno črtno kodo z edinstveno oznako.
18.
EDINSTVENA OZNAKA – V BERLJIVI OBLIKI_ _
PC
SN
NN
23
PODATKI, KI MORAJO BITI NAJMANJ NAVEDENI NA MANJŠIH STIČNIH
OVOJNINAH
Nalepka napolnjene injekcijske brizge
1.
IME ZDRAVILA IN POT(I) UPORABE
Flucelvax Tetra injekcija
cepivo proti gripi
_ _
SEZONA 2023/2024
i.m.
2.
POSTOPEK UPORABE
intramuskularna uporaba
3.
DATUM IZTEKA ROKA UPORABNOSTI ZDRAVILA
EXP
4.
ŠTEVILKA SERIJE
Lot
5.
VSEBINA, IZRAŽENA Z MASO, PROSTORNINO ALI ŠTEVILOM ENOT
0,5 ml
6.
DRUGI PODATKI
24
B. NAVODILO ZA UPORABO
25
NAVODILO ZA UPORABO
FLUCELVAX TETRA SUSPENZIJA ZA INJICIRANJE V NAPOLNJENI INJEKCIJSKI
BRIZGI
cepivo proti gripi iz kulture celic, s površinskimi antigeni,
inaktivirano
PRED ZAČETKOM UPORABE ZDRAVILA NATANČNO PREBERITE NAVODILO, KER
VSEBUJE ZA VAS POMEMBNE
PODATKE!
-
Navodilo shranite. Morda ga boste želeli ponovno prebrati.
-
Če imate
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
PRILOGA I
POVZETEK GLAVNIH ZNAČILNOSTI ZDRAVILA
2
1.
IME ZDRAVILA
Flucelvax Tetra suspenzija za injiciranje v napolnjeni injekcijski
brizgi
cepivo proti gripi iz kulture celic, s površinskimi antigeni,
inaktivirano
2.
KAKOVOSTNA IN KOLIČINSKA SESTAVA
Inaktivirani površinski antigeni (hemaglutinin in nevraminidaza)
virusa influence naslednjih sevov*:
A/Wisconsin/67/2022 (H1N1)pdm09 podoben sev (A/Georgia/12/2022
CVR-167) 15 mikrogramov
HA**
A/Darwin/6/2021 (H3N2) podoben sev (A/Darwin/11/2021, divji tip) 15
mikrogramov HA**
B/Austria/1359417/2021 podoben sev (B/Singapore/WUH4618/2021, divji
tip) 15 mikrogramov
HA**
B/Phuket/3073/2013 podoben sev (B/Singapore/INFTT-16-0610/2016, divji
tip) 15 mikrogramov
HA**
na 0,5-mililitrski odmerek
……………………………………….
*
razmnoženi v celicah pasjih ledvic Madin Darby (MDCK)
**
hemaglutinin
Cepivo je v skladu s priporočili Svetovne zdravstvene organizacije
(SZO) (za severno poloblo) in
priporočili EU za SEZONO 2023/2024.
Cepivo Flucelvax Tetra lahko vsebuje sledi beta-propiolaktona,
cetiltrimetilamonijevega bromida in
polisorbata 80 (glejte poglavje 4.3).
Za celoten seznam pomožnih snovi glejte poglavje 6.1.
3.
FARMACEVTSKA OBLIKA
suspenzija za injiciranje (injekcija)
bistra do rahlo opalescentna tekočina
4.
KLINIČNI PODATKI
4.1
TERAPEVTSKE INDIKACIJE
Preprečevanje gripe pri odraslih in otrocih, starih 2 leti ali več.
Cepivo Flucelvax Tetra je treba uporabljati v skladu z uradnimi
priporočili.
3
4.2
ODMERJANJE IN NAČIN UPORABE
Odmerjanje
_Odrasli in otroci, stari 2 leti ali več _
STAROSTNA SKUPINA
ODMEREK
SHEMA
2 do < 9 let
En ali dva
a
odmerka 0,5 ml.
Če se uporabita 2 odmerka, mora
biti med njima razmik vsaj 4 tedne.
starost 9 let ali več
En odmerek 0,5 ml.
Navedba smiselno ni potrebna.
a
Otroci, mlajši od 9 let, ki predhodno niso bili cepljeni proti gripi,
morajo prejeti drugi odmerek.
_Otroci, mlajši od 2 let _
Varnost in učinkovitost cepiva Flucelvax Tetra pri otrocih, mlajših
od 2 let, nista bili dokazani.
Podatkov ni na vol
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Bulgarian 15-12-2023
Public Assessment Report Public Assessment Report Bulgarian 18-11-2020
Patient Information leaflet Patient Information leaflet Spanish 15-12-2023
Public Assessment Report Public Assessment Report Spanish 18-11-2020
Patient Information leaflet Patient Information leaflet Czech 15-12-2023
Public Assessment Report Public Assessment Report Czech 18-11-2020
Patient Information leaflet Patient Information leaflet Danish 15-12-2023
Public Assessment Report Public Assessment Report Danish 18-11-2020
Patient Information leaflet Patient Information leaflet German 15-12-2023
Public Assessment Report Public Assessment Report German 18-11-2020
Patient Information leaflet Patient Information leaflet Estonian 15-12-2023
Public Assessment Report Public Assessment Report Estonian 18-11-2020
Patient Information leaflet Patient Information leaflet Greek 15-12-2023
Public Assessment Report Public Assessment Report Greek 18-11-2020
Patient Information leaflet Patient Information leaflet English 15-12-2023
Public Assessment Report Public Assessment Report English 18-11-2020
Patient Information leaflet Patient Information leaflet French 15-12-2023
Public Assessment Report Public Assessment Report French 18-11-2020
Patient Information leaflet Patient Information leaflet Italian 15-12-2023
Public Assessment Report Public Assessment Report Italian 18-11-2020
Patient Information leaflet Patient Information leaflet Latvian 15-12-2023
Public Assessment Report Public Assessment Report Latvian 18-11-2020
Patient Information leaflet Patient Information leaflet Lithuanian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Lithuanian 15-12-2023
Public Assessment Report Public Assessment Report Lithuanian 18-11-2020
Patient Information leaflet Patient Information leaflet Hungarian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Hungarian 15-12-2023
Public Assessment Report Public Assessment Report Hungarian 18-11-2020
Patient Information leaflet Patient Information leaflet Maltese 15-12-2023
Public Assessment Report Public Assessment Report Maltese 18-11-2020
Patient Information leaflet Patient Information leaflet Dutch 15-12-2023
Public Assessment Report Public Assessment Report Dutch 18-11-2020
Patient Information leaflet Patient Information leaflet Polish 15-12-2023
Public Assessment Report Public Assessment Report Polish 18-11-2020
Patient Information leaflet Patient Information leaflet Portuguese 15-12-2023
Summary of Product characteristics Summary of Product characteristics Portuguese 15-12-2023
Public Assessment Report Public Assessment Report Portuguese 18-11-2020
Patient Information leaflet Patient Information leaflet Romanian 15-12-2023
Public Assessment Report Public Assessment Report Romanian 18-11-2020
Patient Information leaflet Patient Information leaflet Slovak 15-12-2023
Public Assessment Report Public Assessment Report Slovak 18-11-2020
Patient Information leaflet Patient Information leaflet Finnish 15-12-2023
Public Assessment Report Public Assessment Report Finnish 18-11-2020
Patient Information leaflet Patient Information leaflet Swedish 15-12-2023
Public Assessment Report Public Assessment Report Swedish 18-11-2020
Patient Information leaflet Patient Information leaflet Norwegian 15-12-2023
Summary of Product characteristics Summary of Product characteristics Norwegian 15-12-2023
Patient Information leaflet Patient Information leaflet Icelandic 15-12-2023
Summary of Product characteristics Summary of Product characteristics Icelandic 15-12-2023
Patient Information leaflet Patient Information leaflet Croatian 15-12-2023
Public Assessment Report Public Assessment Report Croatian 18-11-2020